检索结果-南通市图书馆

动态血压再评估可改善非透析慢性肾脏病患者的风险分层

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华高血压杂志 2015年第7期23卷 699-699页

作者： minutolo r Gabbai FB Chiodini P Garofalo C Stanzione G Liberti ME Pacilio M Borrelli S Provenzano M Conte G Nicola L 李金凤叶鹏

在非透析慢性肾脏病风险预后评估中,动态血压比诊室血压更有效,但是动态血压再评估能否进一步明确预后尚未知。研究人员纳入间隔1年行2次动态血压测量的高血压合并非透析慢性肾脏病患者182例,分析由距离基线测量1年后获取的第2次动态血... 详细信息

在非透析慢性肾脏病风险预后评估中,动态血压比诊室血压更有效,但是动态血压再评估能否进一步明确预后尚未知。研究人员纳入间隔1年行2次动态血压测量的高血压合并非透析慢性肾脏病患者182例,分析由距离基线测量1年后获取的第2次动态血压测定值对肾病复合终点（死亡,慢性透析,估算的肾小球滤过率下降≥40%）的评估是否有帮助。

关键词：动态血压测量慢性肾脏病预后评估非透析风险患者研究人员慢性透析

Impact of COVID-19 effective reproductive rate on cryptocurrency

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Financial Innovation 2022年第1期8卷 1432-1458页

作者： Marcel C.minutolo Werner Kristjanpoller Prakash Dheeriya robert Morris University 6001 University BlvdMoon TownshipPA 15108USA Departamento de Industrias Universidad Técnica Federico Santa MaríaAv.España 1680ValparaísoChile California State University Dominguez Hills 1000 E Victoria StCarsonCA 90747USA

The importance of cryptocurrency to the global economy is increasing steadily,which is evidenced by a total market capitalization of over$2.18T as of December 17,2021,according to ***(Coin,2021).Cryptocurrencies are too confusing for laymen and require more *** this study,we analyze the impact that the effective reproductive rate,an epidemiological indicator of the spread of COVID-19,has on both the price and trading volume of eight of the largest digital currencies—Bitcoin,Ethereum,Tether,ripple,Litecoin,Bitcoin Cash,Cardano,and *** hypothesize that as the rate of spread decreases,the trading price of the digital currency *** Generalized Autoregressive Conditional Heteroskedasticity models,we find that the impact of the spread of COVID-19 on the price and trading volume of cryptocurrencies varies by currency and *** findings offer novel insight into the cryptocurrency market and the impact that the viral spread of COVID-19 has on the value of the major cryptocurrencies.

关键词： COVID-19 Cryptocurrency Bitcoin GArCH Digital currency Fintech

Viral Hepatitis B and C Detection among Ebola Survivors and Health Care Workers in Makeni, Sierra Leone

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Biosciences and Medicines 2020年第10期8卷 18-32页

作者： Nadege Goumkwa Mafopa Marta Giovanetti raoul Emeric Guetiya Wadoum Antonella minutolo Claude Kwe Yinda Gianluca russo Béatrice Dambaya Georges Teto Georgia Ambada Patrick Turay Judith Torimiro Alexis Ndjolo Vittorio Colizzi Carla Montesano Chantal BIYA International reference Centre for research on HIV/AIDS Prevention and Management Yaoundé Cameroon University of roma “Tor Vergata” Rome Italy National Institute of Health-ISS Rome Italy University of Makeni Sierra Leone National Institute of Health (NIH) Intramural research Program (IrP) Hamilton Montana USA University di roma “Sapienza” Rome Italy Chantal BIYA International reference Centre for research on HIV/AIDS Prevention and Management University of Yaoundé I Yaoundé Cameroon Holy Spirit Hospital Makeni Sierra Leone Faculty of Medicine and Biomedical Sciences University of Yaoundé I Yaoundé Cameroon

Viral hepatitis B and C infections are among the leading cause of death in Sub-Saharan Africa. Lack of knowledge and awareness in the general population as in health care settings may enhance the propagation of these diseases. We aimed at determining the prevalence of HBV and HCV in Ebola survivors and health care workers (HCWs) of the Makeni town in Sierra Leone. We conducted a cross-sectional study during the last 2013-2016 Ebola outbreak in Makeni among Ebola survivors (N = 68) and 81 Health care workers from Holy Spirit hospital and Loreto clinic, two health care facilities in Makeni district. Serological markers of HBV (HBs Ag, anti-HBs Ab and anti-HBc Ab) and anti-HCV antibodies detection were done using ELISA techniques. The positive detection rates for HBs Ag, anti-HBs Ab and anti-HBc antibodies in Ebola survivors were 23.53% (16/68), 32.35% (22/68) and 88.89% (16/18) respectively. Survivors with a current HBV infection had a positive rate of 38.89% (7/18) and 16.66% (3/18) of them were considered immune due to past HBV infection. HCV prevalence was 26.47% (18/68) and about 10.29% (7/68) were HBV/HCV co-infected. The positive detection rates of HBsAg, anti-HBs Ab and anti-HBc Ab were 37.07% (30/81), 33.33% (27/81) and 30.86% (25/81) respectively in health care workers. We observed that 4.94% (4/81) of the HCWs were currently infected with HBV. Participants considered as immune due to past infection represented 23.47% (19/81) and those immune due to vaccination represented 2.47% (2/81). The prevalence of HCV infection among health staff was 2.47% (2/81) with 1.23% (1/81) being HBV/HCV co-infection. Our findings showed that viral hepatitis infection is a burden for Sierra Leone government. There is an urgent need to develop and implement strategies that could improve population immunization against HBV and vulgarization of HCV treatment programs.

关键词： Viral Hepatitis B and C Ebola Survivors Health Care Workers

Immunoglobulin G Specific Antibody Level against Ebola Viral Glycoprotein and Nucleoprotein in Ebola Virus Disease Survivors and Their relatives

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Biosciences and Medicines 2021年第4期9卷 179-196页

作者： Nadège Goumkwa Mafopa raoul Emeric Guetiya Wadoum Marta Giovanetti Antonella minutolo Béatrice Dambaya Claude Kwe Yinda Gianluca russo Georges Teto Georgia Ambada Patrick Turay Judith Torimiro Alexis Ndjolo Jules roger Kuate Vittorio Colizzi Carla Montesano Chantal BIYA International reference Centre for research on HIV/AIDS Prevention and Management Yaoundé Cameroon University of roma “Tor Vergata” Rome Italy Department of Biochemistry University of Dschang Dschang Cameroon Departement of Public Health University of Makeni Makeni Sierra Leone National Institute of Health—ISS Rome Italy Faculty of Science University of Yaoundé I Yaoundé Cameroon Intramural research Program National Institute of Health Bethesda Maryland USA University di roma “Sapienza” Rome Italy Holy Spirit Hospital Makeni Makeni Sierra Leone Faculty of Medicine and Biomedical Sciences University of Yaoundé I Yaoundé Cameroon

Ebola virus disease is a complex zoonosis that is highly virulent in humans. Despite its sorely pathogenic and lethal nature, survivors of this infection and even asymptomatic cases are able to develop both humoral and cellular immunity against several Ebola virus (EBOV) proteins. We aimed at determining immunoglobulin G (IgG) antibodies level against two Ebola viral antigens, the glycoprotein and the nucleoprotein in Ebola survivors and their relatives. Anti-EBOV glycoprotein (GP) and nucleoprotein (NP) IgG antibodies were quantified using ELISA. We enrolled 199 participants in two different sites as follow: 91 survivors at the Loreto clinic and 70 survivors with 38 relatives of Sierra Leone Association of Ebola Survivors Bombali Branch (SLAESB) tested for anti-EBOV NP and anti-EBOV GP IgG antibodies. Our findings revealed that the median anti-EBOV IgG level among survivors was 5.7128 U/ml [IQr: 2.793 - 7.783] for anti-EBOV GP IgG and 4.431 U/ml [IQr: 2.083 - 7.696] for anti-EBOV NP IgG. Survivors relatives had a median anti-EBOV GP IgG level of ?0.7128 U/ml [IQr: -0.903 to -0.04327] and -2.711 U/ml [IQr: -4.01 to -1.918] for anti-EBOV NP IgG. We observed that IgG levels in survivors were higher than in relatives with a significant difference of about 0.0001. The median value of anti-EBOV IgG level among seropositive relatives was 0.7043 U/ml [IQr: 0.5686 to 3.716] for anti-EBOV GP IgG and 4.05 U/ml [IQr: 0.2765 to 7.759] for anti-EBOV NP IgG respectively. Interestingly, we observed that 3.30% of Loreto clinic survivors did not developed anti-EBOV NP IgG antibodies;also about 10% survivors of the SLAESB were not reactive to anti-EBOV NP IgG and 1.43% of these survivors did not express antibodies against the Ebola viral glycoprotein. Our work is consistent with previous published studies showing heterogeneity in both survivors and asymptomatic cases of Ebola infection developing adaptive immunity against EBOV proteins.

关键词： Immunoglobulin IgG Level Ebola Survivors and relatives Glycoprotein and Nucleoprotein